Seattle Genetics is a Bothell-based Cancer Drug Company that has been making significant investments in its product line. It has also embarked on hiring many employees. The company is succeeding in expanding the use of Adcetris, its first drug. The expansion program includes the development of 12 new drugs and recruiting over 100 employees. Some will work in the U.S. and others in its Switzerland office. Seattle Genetics is testing Adcetris against different types of lymphomas. The company will conduct a more advanced phase of clinical trial. The only commercialized drug, Adcetris, will be used as the main drug in treatment of new diagnosis of Hodgkin Lymphoma and its previous untreated cases.
Clay Siegall, CEO of Seattle Genetics, said that the results of the trials would mark a major milestone in the program. Adcetris is widely used to treat Lymphoma patients. The drug earned the company huge revenues of $226 million from sales in Canada and U.S. in 2015. There is a high possibility that the sales proceeds will increase this year. Seattle Genetics partnered with Takeda Pharmaceutical to sell the drug outside Canada and the U.S. Among the 12 drugs that are being manufactured, one drug is for treating acute myeloid leukemia- 33A, two drugs for bladder cancer and one drug for breast cancer. These drugs will be tested in subsequent clinical trials. This information was originally mentioned on bizjournals.com.
About Clay Siegall
Clay Siegall is the principal, CEO, and Chairman of the Board of Directors of Seattle Genetics, a company that he co-founded in 1998. Clay has provided Seattle Genetics’s employees with a favorable environment to develop a wide range of cancer treatments. They include ADCETRIS, a drug that was approved in 2011 by the U.S. Food and Drug Administration (FDA). Under his leadership, Seattle Genetics has secured over $675 million from both public and private funding. Before co-founding Seattle Genetics, Siegall worked for other companies like the National Cancer Research and Bristol-Myers Squibb Pharmaceutical Research Institute. He plays an active role as a member of the Board of Directors for Alder BioPharmaceuticals and Mirna Therapeutics. Clay is a successful author with more than 70 publications. He is a graduate of the renowned George Washington University where he earned a PhD in Genetics. He is also an alumnus of the esteemed University of Maryland where he pursued a B.S. in Zoology. This information was originally published on CrunchBase.